Skip to content
Menu

Nexalin Technology, Inc. NXL

Full chart Compare
Set alert

Price alert · NXL

All alert types
1.39 USD -0.09 (-6.08%)

Regular-session close

1.42 +0.03 +2.34%

After hours · Nov 19, 5:58 PM ET

1.39 Day range 1.48
1.39 52-week range 32.70
YTD
-91.70%
1 year
-95.59%

5D +0.04 (+2.58%)

1.401.501.60FriMonTueWedThu1.44
Market cap
1.72M
Revenue (ttm)
150.16K
EPS (ttm)
-13.21
Shares out
12.86M
Forward P/E
-6.39
YTD return
-91.70%
1-year return
-95.59%
Volume
9.97K
Avg volume
1.04M
Open
1.40
Previous close
1.48
Day's range
1.39 – 1.48
52-week range
1.39 – 32.70
Beta
3.57

Key statistics

50-day average
3.12
200-day average
1.64
Enterprise value
39.38M
Price / sales
224.41
Price / book
6.08
Revenue growth
-24.50%
Free cash flow
-1.75M
Total cash
848.80K
Return on equity
-202.23%
Short % of float
1.03%

Fundamental scorecard

4 of 25 checks passed on NXL’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NXL Revenue — quarterly 78.30K
NXL Net income — quarterly -2.66M
NXL EPS — quarterly -3.43

Earnings

NXL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 8, 2024Sep 1, 20240.00-0.23——
Aug 8, 2024Jun 1, 20240.00-0.17——
May 10, 2024Mar 1, 20240.00-0.14——
Mar 27, 2024Dec 1, 20230.00———
Nov 13, 2023Sep 1, 20230.00-0.31——
Aug 10, 2023Jun 1, 20230.00———

Upgrades / downgrades

NXL analyst upgrades and downgrades
DateFirmActionFromTo
Dec 5, 2024Maxim GroupdownBuyHold
Oct 9, 2024Maxim Groupinit—Buy

About Nexalin Technology, Inc.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
nexalin.com

News

Your note

Sign in to keep a note on NXL — it syncs with the Stock Master app.

Insider holders

NXL insider holders
InsiderRelationLatest transactionDateShares held
BERNHARD LESLIEDirectorStock Award(Grant)Sep 29, 202449,838
ELSON MARILYNBeneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Sep 29, 20241,535,240
HU BENJAMINDirectorStock Award(Grant)Sep 29, 2024340,636
OWENS DAVIDOfficer and DirectorPurchaseOct 27, 2024148,293

Institution ownership

NXL institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC0.80%102,900269.60KSep 29, 2024
Geode Capital Management, LLC0.61%78,697206.19KSep 29, 2024
Citadel Advisors Llc0.45%58,185152.44KSep 29, 2024
CVI Holdings, LLC0.43%55,462145.31KJun 29, 2024
Susquehanna International Group, LLP0.33%42,383111.04KSep 29, 2024
Vanguard Group Inc0.25%31,78083.26KSep 29, 2024

Fund ownership

NXL fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.41%52,237136.86KOct 30, 2024
Vanguard Extended Market Index Fund0.25%31,78083.26KSep 29, 2024
Fidelity Total Market Index Fund0.13%17,07944.75KOct 30, 2024
Fidelity Series Total Market Index Fund0.10%12,29632.22KOct 30, 2024